Contents:

1.RNAi Market & Business Models Overview of RNA Interference Double Stranded RNA (dsRNA) Small interfering RNA (siRNA) Short Hairpin RNA (shRNA) DNA-directed RNAi (ddRNAi) MicroRNA (miRNA) The RNAi Market & Key Customer Applications The WW RNAi Market RNAi Tools for Research, Drug Discovery & Development As Tools for Basic Research As Tools for Drug Discovery As Tools for Drug Development RNAi-as-Drugs (Therapeutics) Competitive Market Market Map of Major Players Research Findings & Analysis Market Leaders RNAi Moves Upstream on the Drug R&D Path Technology Big Picture Business Model & Product Development Strategies 2.M&A and Alliance Activities Analysis of RNAi M&As and Alliances, 2005 to July-2007 RNAi Alliances and M&As, 2005 to June-2007 Intellectual Property and Regulatory Approval Intellectual Property Regulatory Approval Findings: Companies to Watch for Future R&D RNAi Technology Companies on the Move Big Pharma is Involved in RNAi 3.Market Forecast and Trends The WW RNA Interference (RNAi) Market Size 2006-2011 WW RNAi Market by Segments RNAi Market By WW Regions RNAi Market By Application Segments RNAi in Basic Research RNAi in Drug Discovery RNAi in Drug Development RNAi Therapeutics RNAi Application Segment Market Shares, 2007 & 2011 RNAi Market By Major Disease Segments Cancer Infections Metabolic Eye disease CNS Respiratory Inflammation Bone Diseases Blood Disease Cardiovascular Diagnostics, Skin Conditions and Others Major Disease Segment Market Shares (%), 2007 & 2011 RNAi Market By Product Segments RNAi Reagents & Related Services RNAi Delivery Tools & Devices Assay Systems Cell Lines & Related Discovery Techs, Services & Drugs Genomewide RNAi HT/ HC Screening Tools RNAi Product Segment Market Shares (%), 2007 & 2011 Key Trends/ Future Directions Big Pharma Starting to Get Involved in RNAi Advances Made in Dealing With Off-target Effects Growing Knowledge About microRNAs Direct Delivery of RNAi-based Drugs Systemic Delivery of RNAi Drugs RNAi Future Direction Timeline 4.Selected Companies Working in RNAi Alnylam Pharmaceuticals, Inc. Ambion, Inc. Avalon Pharmaceuticals, Inc. Benitec, Ltd. Cenix Bioscience GmbH CytRx Corporation Dharmacon, Inc. Integrated DNA Technologies, Inc. (IDT) Intradigm Corporation Intronn, Inc. Invitrogen Corporation Lentigen Corporation Mirus Bio Corporation Nastech Pharmaceutical Company Inc. Open Biosystems Opko Health, Inc. Panomics, Inc. RNAx GmbH Sirna Therapeutics, Inc. Targeted Genetics Corporation 5.Findings and Suggestions Review of Findings and Key Trends RNAi Technology Competitive Landscape M&As and Alliances Patents Market Assessment Recommendations to Capture Opportunities Products Needed by RNAi Users in R&D Future Market Prospects 6.Appendix RNAi Glossary Company Contacts About Takeda Pacific About the Authors List of Tables Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs Table 3. Major Players in the RNAi Market Table 4. Major Players by Focus Segment and Product Strategy Table 5. Summary of RNAi M&As and Alliances, 2005 to July-2007 Table 6. M&As and Alliances, Jan-July/ 2007 Table 7. M&As and Alliances, 2006 Table 8. M&As and Alliances, 2005 Table 9. RNAi Related Patent Applications (US), 2002-1H2007 Table 10. Key Patents for RNAi Reagents and Drugs Table 11. RNAi Therapeutics In /(or Near) Clinical Trials Table 12. Top RNAi Alliance Players: RNAi Technology Companies Table 13. Top RNAi Alliance Players: Big Pharmas Table 14. WW RNAi Market Size By Total Revenues ($M), 2006-2011 Table 15. WW RNAi Market By WW Regions and Revenues, 2006-2011 Table 16. WW Regions Market Shares (%), 2007 & 2011 Table 17. US RNAi Market By Application Segment Revenues ($M), 2006-2011 Table 18. Application Segment Market Shares (%), 2007 & 2011 Table 19. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011 Table 20. Major Disease Segment Market Shares (%), 2007 & 2011 Table 21. RNAi Market By Product Segments, Revenues ($M), 2006-2011 Table 22. Product Segment Market Shares (%), 2007 & 2011 Table 23. RNAi R&D Unmet Needs - Selected Opportunity Matrix List of Illustrations Figure 1. Timeline for Key RNAi Technology Developments Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC Figure 4. RNAi R&D Market by Major Applications Figure 5. RNAi Related Patent Applications (US), 2002-1H2007 Figure 6. New Drug Approval Timeline and Roadmap Figure 7. WW RNAi Market Size By Total Revenues ($M), 2006-2011 Figure 8. WW RNAi Market By WW Regions and Revenues, 2006-2011 Figure 9. WW RNAi Market By WW Regions and Shares, 2007 & 2011 Figure 10. WW RNAi Market By Application Segment Revenues, 2006-2011 Figure 11. RNAi Application Segment Market Shares (%), 2007 & 2011 Figure 12. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011 Figure 13. Major Disease Segment Market Shares (%), 2007 & 2011 Figure 14. RNAi Market By Product Segments, Revenues ($M), 2006-2011 Figure 15. Product Segment Market Shares (%), 2007 & 2011 Figure 16. RNAi Future Direction Timeline to 2011

Companies Mentioned

Alnylam Pharmaceuticals, Inc. Ambion, Inc. Avalon Pharmaceuticals, Inc. Benitec, Ltd. Cenix Bioscience GmbH CytRx Corporation Dharmacon, Inc. Integrated DNA Technologies, Inc. (IDT) Intradigm Corporation Intronn, Inc. Invitrogen Corporation Lentigen Corporation Mirus Bio Corporation Nastech Pharmaceutical Company Inc. Open Biosystems Opko Health, Inc. Panomics, Inc. RNAx GmbH Sirna Therapeutics, Inc. Targeted Genetics Corporation